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Abstract
Tight glycaemic control has emerged as a major focus in critical
care. However, the struggle to repeat, improve and standardize the
results of the initial landmark studies is ongoing. The prospective
computerized glycaemic control study by Shulman et al. highlights
two emerging and often overlooked aspects of intensive insulin
therapy protocols beyond simple glycaemic performance. First, the
clinical ergonomics and ability to integrate into the critical care unit
workflow must be considered as they may impact results and
definitely affect uptake. Second, the real lessons of any protocol’s
performance are likely to be best realized by comparison with other
results, a task that is very difficult without a consensus method of
reporting that allows such comparisons across studies. Embracing
these issues will take the field closer to accepted, repeatable
approaches to tight glycaemic control.
That tight glycaemic control in critical care saves lives is
increasingly less questioned. In contrast, the how and for
whom remains quite elusive. In this journal, Shulman et al. [1]
report the results of another prospective glycaemic control
study utilizing a computerized protocol to implement a
relatively complex protocol.
Tight control has been of great interest since the landmark
studies of Van den Berghe et al. [2,3] and Krinsley [4]. At
least two to three further, large, randomized trials have been
started, including the ongoing Normoglycemia in Intensive
Care Evaluation (NICE)-Survival Using Glucose Algorithm
Regulation (SUGAR) studies [5], and the discontinued
Efficacy of Volume Substitution and Insulin Therapy in
Severe Sepsis (VISEP) study [6]. Finally, several prospective
studies, primarily focused on developing new protocols,
have been published, to the extent that reviews have recently
appeared [7-9].
Two common themes emerge that are also evident in this
study. The first concerns the impact of clinical burden on the
results obtained. The second is one of performance. What
defines good performance, and what level is required to
achieve the mortality and economic [10,11] outcomes of the
landmark studies?
The clinical burden of intensive insulin therapy (IIT) has not
gone unnoticed [12,13]. Shulman and colleagues, have
uniquely addressed this issue directly by tracking compliance
in the timing of glucose measurements and thus perhaps
compliance and performance in control. Only 53%
(interquartile range: 41 to 67%) of glucose measurements
were performed in the specified one to two hour timeframe,
including a 50% (30 to 60 minutes) buffer. This result is
unique in the field and clearly shows for the first time the
difficulty of integrating any protocol into the typically hectic
intensive care unit (ICU) environment.
In contrast, Van den Berghe et al. [2,3] utilized additional staff
to reduce burden and avoid contamination across their ran-
domized trial. The higher average glycaemic control obtained
by Krinsley [4] without such extra staffing thus indicates the
(potential) impact of clinical burden on performance. This
paper thus clearly highlights the little addressed issue of
human factors and the need to consider them explicitly in
protocol design – perhaps including experts in the field – to
obtain more consistent results. More succinctly, it may not be
the protocol but the ability to implement it effectively that
prevents success in some cases.
Regarding performance, patients in this study were in the
target 4.4 to 6.1 mmol/L band, a median of 23.1% (15.4 to
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29.1%) of the time, with a further 48.5% (36.9 to 60.8%) in
the 6.2 to 7.99 mmol/L band. The authors conclude that the
protocol “did not achieve tight glycaemic control for a
substantial portion of each patient’s stay”. However, their
results are similar in average value and tighter in distribution
than the very successful results of Krinsley [4], based on
values estimated from Figure 2 and Table 4 in Krinsley's
original work [4] and the data presented by Shulman et al.
They are also similar to other studies [14-16].
This contradiction illustrates the almost complete inability to
assess or compare performance consistently across studies.
A review of 24 studies [7] shows that five use percentage
time in a single band, while most others use a mean value and
standard deviation. Target range and measurement frequency
also varied considerably. Combined with differences in cohort
and critical illness, it is very difficult to take significant lessons
away from many of these studies. This is not a fault of the
study authors or implementation, but a lack of a consensus
means of reporting.
Shulman et al., provide significant insight into their results
compared to many others, reporting percentage time in
bands on a per patient basis as well as indicating the varia-
bility across the cohort via the box and whiskers plot of Figure 2.
From this data and Table 4 it is possible to determine both
median and variability on a per patient basis – the same basis
on which tight control has a clinical impact. It is also some-
thing not reported in most similar studies, making this study
unique for its transparency. Variability is particularly important
as a recent study of over 7,000 patients showed that the
glycaemic variability is an independent predictor of mortality
[17], and thus a potentially critical performance measure.
In contrast, almost all studies report glycaemic control in
terms of overall results, rather than per patient. Thus, one
could (in extreme) report relatively wide variability for a
protocol, when in fact each patient was tightly controlled
within that range – or vice versa. Shulman et al.’s complete
and transparent per patient reporting is a stronger template
on which to make comparisons and derive lessons learned.
Thus, a second clear outcome highlighted by this study is the
need for a consensus statement with regard to reporting
glycaemic control performance. A better understanding would
result from specifying a minimum standard that included per
patient and overall results for a series of accepted glycaemic
ranges and thus variability. This call is not necessarily new
[18], but perhaps bears repeating.
More succinctly, a standard method of reporting results
would enable easier comparison across studies and cohorts,
with an ultimate goal of enabling better understanding of
what performance metrics (time in band, variability, etc) are
important. Coupled with improved ergonomics and
integration into typical ICU environments, the potential to
create consistently repeatable results will increase, potentially
substantially. And thus, we might well be able to begin
answering the difficult questions of how and for whom”.
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